Description
Mubritinib is an EGFR2 (HER2) inhibitor that underwent clinical trials, showing some promise as an anticancer chemotherapeutic in the treatment of bladder, kidney, and prostate cancer, but was not pursued further.
Product Unit Size | Cost | Quantity | Stock |
---|
Mubritinib is an EGFR2 (HER2) inhibitor that underwent clinical trials, showing some promise as an anticancer chemotherapeutic in the treatment of bladder, kidney, and prostate cancer, but was not pursued further.
Cas No. | 366017-09-6 |
---|---|
Purity | ≥99% |
Formula | C25H23F3N4O2 |
Formula Wt. | 468.47 |
Chemical Name | 1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole |
IUPAC Name | 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4- (trifluoromethyl)phenyl]ethenyl]-1,3-oxazole |
Synonym | TAK-165 |
Appearance | White to off white powder |
Store Temp | Ambient |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Nagasawa J, Mizokami A, Koshida K, et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol. 2006 May;13(5):587-92. PMID: 16771730.
IMPDH inhibitor.
Nicotinamide analog prodrug; fatty acid synthet...
Nitroimidazole; hypoxic modifier and radiosensi...
Calcineurin inhibitor.
Benzimidazole; microtubule polymerization inhib...
p110α PI3K inhibitor.
5-Nitroimidazole derivative; genotoxic.
Synthetic peptide; FPRL1 agonist.
Induces ER degradation.
Impurity of diclofenac
Endogenous bombesin-related peptide, involved i...
Polymer precursor
GABA-A antagonist.
Fluoroquinolone; bacterial DNA gyrase inhibitor...
Glycopeptide, vancomycin analog; peptidoglycan ...
Peptide found in insects.
Diterpene found in coffee beans.
Read-through agent and nonsense mutation target...
Cortisol derivative; glucocorticoid agonist.
Peptide, urocortin II analog; CRFR2 agonist.